Azenosertib OS Separation Confirmed: 15.9 vs 7.5 Months in Cyclin E1-Positive Ovarian Cancer
ZNTL sits 91% above its 52-week low of $1.212 on light trading volume (0.1× avg).
Summary
Zentalis presented the full DENALI Part 1b interim dataset at ESMO, showing median overall survival of 15.9 months in Cyclin E1-positive platinum-resistant ovarian cancer versus 7.5 months in Cyclin E1-negative patients — a clean separation that supports Cyclin E1 as a predictive biomarker for azenosertib. The response data back it up: 37.2% ORR in response-evaluable Cyclin E1-positive patients (n=43) and 33.3% across all 48 positive patients, with median duration of response of 5.5 months and two responses beyond 15 and 20 months. Safety was consistent with prior reporting, though 19.6% discontinued for treatment-related adverse events and median relative dose intensity held at 84.6%. This is the detail behind the Oct 18 Reuters report of the first OS analysis, and it lands ahead of the registration-intended DENALI Part 2 and the ASPENOVA Phase 3 confirmatory trial, which the company says is designed to support accelerated approval pending positive outcomes and further FDA discussions. With a small market cap and cash runway into late 2027, the biomarker story is the whole thesis — these numbers keep it intact.
At the time of this announcement, ZNTL was trading at $2.31 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $218.7M. The 52-week trading range was $1.21 to $6.95. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.